CD19-targeted CAR-T-cell therapy is a novel therapeutic that uses engineered T-cells with chimeric antigen receptors against CD19 for the treatment of acute lymphoblastic leukemia (ALL) and adult B-cell lymphomas. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.